Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer

NCT04034927 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04034927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04034927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 4, 2019
Completion date
February 21, 2027
Enrollment
61 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube endometrioid tumor, fallopian tube high grade serous adenocarcinoma, malignant ovarian endometrioid tumor, ovarian high grade serous adenocarcinoma, platinum-sensitive fallopian tube carcinoma, platinum-sensitive ovarian carcinoma, platinum-sensitive primary peritoneal carcinoma, primary peritoneal high grade serous adenocarcinoma, recurrent fallopian tube carcinoma, recurrent fallopian tube endometrioid adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian serous adenocarcinoma, recurrent primary peritoneal carcinoma, recurrent primary peritoneal endometrioid adenocarcinoma